We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-16.09%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.65B
AUM Growth
-$1.07B
Cap. Flow
-$484M
Cap. Flow %
-29.24%
Top 10 Hldgs %
45.81%
Holding
77
New
–
Increased
10
Reduced
34
Closed
14

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$12.8M
2
COGT icon
Cogent Biosciences
COGT
+$6.35M
3
ESTA icon
Establishment Labs
ESTA
+$5.01M
4
ANNX icon
Annexon
ANNX
+$4.78M
5
ISRG icon
Intuitive Surgical
ISRG
+$4.1M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$83.3M
2
KRYS icon
Krystal Biotech
KRYS
+$81.8M
3
ABT icon
Abbott
ABT
+$29.8M
4
ALGN icon
Align Technology
ALGN
+$28.6M
5
FOLD
Amicus Therapeutics
FOLD
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LVTX
51
DELISTED
LAVA Therapeutics
LVTX
$3.73M 0.23%
2,074,372
– –
IVVD icon
52
Invivyd
IVVD
$284M
$3.37M 0.2%
3,065,714
+1,624,989
+113% +$3.59M
CABA icon
53
Cabaletta Bio
CABA
$529M
$3.31M 0.2%
442,826
– –
GRTS
54
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$3.16M 0.19%
5,107,732
-647,343
-11% -$547K
ALLK
55
DELISTED
Allakos
ALLK
$3.08M 0.19%
3,077,828
-373,248
-11% -$443K
XERS icon
56
Xeris Biopharma Holdings
XERS
$1.55B
$2.35M 0.14%
1,046,587
– –
RAPT
57
DELISTED
RAPT Therapeutics
RAPT
$1.64M 0.1%
67,085
-15,715
-19% -$726K
KLRS
58
Kalaris Therapeutics
KLRS
$95.9M
$1.38M 0.08%
82,955
– –
ACHL
59
DELISTED
Achilles Therapeutics
ACHL
$1.31M 0.08%
1,608,089
– –
LAB icon
60
Standard BioTools
LAB
$252M
$729K 0.04%
411,631
– –
ADAP
61
DELISTED
Adaptimmune Therapeutics
ADAP
$698K 0.04%
715,607
– –
HOOK
62
DELISTED
HOOKIPA Pharma
HOOK
$630K 0.04%
106,377
– –
TKNO icon
63
Alpha Teknova
TKNO
$382M
$212K 0.01%
154,509
-16,944
-10% -$32.2K
ABT icon
64
Abbott
ABT
$195B
– –
-262,371
Closed -$29.8M
ALGN icon
65
Align Technology
ALGN
$11.2B
– –
-87,255
Closed -$28.6M
APLS
66
DELISTED
Apellis Pharmaceuticals
APLS
– –
-155,000
Closed -$9.11M
CI icon
67
Cigna
CI
$73.7B
– –
-65,435
Closed -$23.8M
DGX icon
68
Quest Diagnostics
DGX
$26.8B
– –
-83,849
Closed -$11.2M
ELAN icon
69
Elanco Animal Health
ELAN
$12B
– –
-676,039
Closed -$11M
ELV icon
70
Elevance Health
ELV
$85.5B
– –
-31,223
Closed -$16.2M
EVH icon
71
Evolent Health
EVH
$520M
– –
-679,172
Closed -$22.3M
HCA icon
72
HCA Healthcare
HCA
$90.5B
– –
-52,487
Closed -$17.5M
ICLR icon
73
Icon
ICLR
$13.1B
– –
-36,949
Closed -$12.4M
MCK icon
74
McKesson
MCK
$104B
– –
-20,707
Closed -$11.1M
PEN icon
75
Penumbra
PEN
$12.7B
– –
-44,613
Closed -$9.96M
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2024 Portfolio in Review

As of Q2 2024, Redmile Group held 77 positions worth $1.65B, down 39% from $2.72B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $484M in Q2 2024, closing 14 positions and reducing 34 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $83.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group added an estimated $12.8M to Replimune Group.

  • Redmile Group added most to Replimune Group in Q2 2024, an estimated $12.8M increase.
  • Redmile Group's biggest Q2 2024 reduction was Krystal Biotech, cutting an estimated $81.8M.
  • Redmile Group fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2024, selling an estimated $83.3M.
  • Redmile Group's ten largest holdings make up 46% of its $1.65B portfolio in Q2 2024.
  • Redmile Group opened 0 new positions and closed 14 in Q2 2024.
  • Redmile Group's portfolio value fell 39% quarter-over-quarter to $1.65B.

Based on Redmile Group's 13F filing for Q2 2024, filed 14 Aug 2024.